122 results about "Chimera Protein" patented technology

The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.

The invention discloses a method for improving the inductivity and genetic transformation efficiency of hairy roots of toona ciliata. According to the method, agrobacterium rhizogenes carrying RUBY-TcGRF8-GIF2 chimeric protein are injected into stems and petioles of aseptic seedlings of the toona ciliata, and the TcGRF8-GIF2 chimeric gene is over-expressed, so that the induction efficiency and the genetic transformation efficiency of the toona ciliata hairy roots are remarkably improved, and the transformation period of the toona ciliata hairy roots is remarkably shortened. Specifically, after overexpression of the TcGRF8-GIF2 gene, the induction time of the hairy roots is shortened from 70 days of a RUBY-XbaI no-load plasmid control group to 25 days, the induction rate and conversion rate of the hairy roots mediated by agrobacterium tumefaciens are improved, the operation efficiency of genetic transformation of the toona ciliata is effectively improved, and the method has important significance for promoting genetic improvement of the toona ciliata.

The invention discloses a rice large-scale metabolism regulator DGP1 and crop metabolism quality design. The invention finds that the structural domain of the rice DGP1 family protein TIGR01589 targets a plurality of metabolic enzymes and promotes the metabolic enzymes to be transferred to a cell nucleus; the structural domain also has an intervention effect on a light breathing pathway by changing the composition of a glycine decarboxylase compound in mitochondria. Based on a molecular mechanism of DGP1, a chimeric protein ST containing a conservative structural domain and coupled with a chloroplast positioning signal is designed, and genetic engineering modification of pakchoi is realized. The modification strategy not only can guide substrate flow of a central glycolysis pathway to flavonoid biosynthesis, but also can promote accumulation of saccharides derived from photosynthetic products in leaves.

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen, which comprises the following antigen components: at least one fusion protein or chimeric protein formed by mycobacterium tuberculosis early secretion antigens Ag85A and Ag85B and / or immunocompetence fragments thereof, at least one mycobacterium tuberculosis PE / PPE family antigen Rv1759c (PE-PGRS family protein WAG22) or immunocompetence fragments thereof, and at least one immunocompetence fragment thereof, and at least one mycobacterium tuberculosis latent associated antigen Rv1813c or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

The present application provides, in part, pharmaceutical formulations of Clec9A-based chimeric protein complexes and uses thereof.

Aspects of the present disclosure include chimeric proteins and engineered host cells that comprise the chimeric proteins. Another aspect of the present disclosure include methods of reducing porphyrins or derivatives thereof from recombinant proteins expressed or secreted from the engineered host cell. Another aspect of the present disclosure includes methods of making recombinant proteins from the engineered host cells.

The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D′ domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.

Described herein are multicistronic expression systems that encode chimeric proteins, specifically membrane-cleavable chimeric systems and chimeric antigen receptors for administration in combination with the cytokine IL2 for treating a subject having cancer. Also described herein are nucleic acids, cells, and methods directed to the same. Also described herein are methods of stimulating a cell-mediated immune response to a tumor, reducing tumor volume, or providing an anti-tumor immunity in a human subject in need thereof, the methods comprise administering to a subject multiple administrations of an immunoresponsive cell encoding a controlled release cytokine.

The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in anti-rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing gene fragments of the ectodomain of the G glycoprotein of the Pasteur strain rabies virus, a linker of 7 amino acids (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the gp64 baculovirus protein, with the arrangement of the sequences in the designed gene cassette being shown in figure 1.

The present invention relates, in part, to chimeric proteins and Fc-based chimeric protein complexes comprising IL-6 or modified IL-6 and their use as therapeutic agents. The present invention further relates to methods of treatment of various diseases, such as cancer.

The present invention relates to a chimeric protein of IL-2 protein and IL-15 protein, a variant thereof, a fusion protein comprising the same, and / or a genetically engineered cell modified to express any one or more thereof. In the present invention, the binding to IL-2Rβ is weakened, the side effects caused by the excessive immune cell activity of IL-2 can be inhibited, and the rapid exhaustion of natural killer cells is prevented, thereby allowing the appropriate level of cell activity and cell survival ability to be maintained for a long time. Accordingly, the present invention can be used for modulating the immune system and treating immune-related diseases, such as cancer, infectious diseases, and autoimmune diseases.

The present invention provides a chimeric protein comprising a first polypeptide comprising a FVIII protein and a first Ig constant region or a portion thereof; and a second polypeptide comprising a VWF protein comprising a D' domain and a D3 domain of VWF, an XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with one another. The present invention also includes nucleotides, vectors, host cells, methods of using the chimeric protein.

In the present invention, there is discovered a novel mRNA vaccine for preventing respiratory syncytial virus (RSV) infections, the mRNA vaccine being superior in terms of immunogenicity and pharmacological efficacy compared with RSV FG chimeric protein vaccines each comprising RSV F and G proteins and mRNA vaccines which have been produced on the basis of Japanese Patent No. 7253034 (Patent Document 7). In the present invention, an RSV FG chimeric mRNA vaccine is produced by inserting a highly conserved domain of the RSV G protein into a basic skeleton that is formed by linking a transmembrane region to an RSV F protein ectodomain. As a result of performing evaluation on immunogenicity and pharmacological efficacy, it has been confirmed that the immunogenicity and pharmacological efficacy of the RSV FG chimeric mRNA vaccine of the present invention are superior compared with those of the RSV FG chimeric protein vaccines and mRNA vaccines which have been produced on the basis of Patent Document 7.

The present disclosure provides compositions and methods for cell transplantation therapy based on forced expression of an exogenous HLA-F protein in donor cells to be transplanted into a subject. In some embodiments, the donor cells express an exogenous chimeric HLA-F protein comprising an extracellular region comprising an HLA-F alpha 1 domain, an HLA alpha 2 domain, an HLA-F alpha 3 domain, a linker and a β2m protein.

The application discloses a kind of chimeric proteins, including cytokine and cytokine receptor extracellular domain;Cytokine is embedded in the chimeric region of cytokine receptor extracellular domain, and the chimeric region is located in the flexible connection region of cytokine receptor extracellular domain, or the chimeric region is located in the flexible connection region of the cytokine of cytokine receptor extracellular domain embedded in this cytokine.The application discloses that by selecting suitable chimeric region on CD25 and IL-2 protein, two proteins are divided into different peptide segments, are connected to form a peptide chain, and are expressed to form chimeric protein.It has eliminated or reduced affinity for high-affinity IL-2 receptor (IL-2Rαβγ), and retains / enhances the affinity for medium-affinity IL-2 receptor (IL-2Rβγ).The application also discloses chimeric proteins of IL15RA and IL-15 and chimeric proteins of IL21R and IL21.The application also discloses conjugates, pharmaceutical compositions, nucleic acid molecules, expression vectors, host cells, production methods, kits of the chimeric protein, and uses thereof.

This invention relates to the application of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 in the preparation of a kit for detecting avian adenovirus serotype 4 antibodies. The amino acid sequence of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 is shown in SEQ ID NO.1. This invention utilizes the multi-epitope recombinant chimeric protein rcF2 to establish an indirect ELISA detection method and kit for detecting avian adenovirus serotype 4. This recombinant chimeric protein can be recognized by avian adenovirus serotype 4 positive sera, and the detection sensitivity of positive sera samples can reach 1:16000. It shows no cross-reactivity with antibodies against other pathogens, indicating that the ELISA detection method based on this multi-epitope recombinant chimeric protein rcF2 is simple to operate, enhances detection sensitivity, and has good specificity and repeatability.

The invention concerns a chimeric protein CTX-CNF1, or a pharmaceutical composition comprising it, for use in stimulating the immune system in immunogenic and non- immunogenic tumors. A pharmaceutical kit comprising the chimeric protein CTX-CNF1 and uses thereof are also described.

The invention belongs to the field of transgenic animals, and relates to an MET gene modified non-human animal. Specifically, the present invention provides a method of making a genetically modified non-human animal comprising modifying a non-human animal genome such that the modified non-human animal genome comprises a nucleotide sequence encoding a human or chimeric hepatocyte growth factor receptor (MET) protein. Also provided is a genetically modified non-human animal genome comprising a nucleotide sequence encoding a human or chimeric MET protein. The non-human animal obtained by the method provided by the invention provides a powerful tool for researching the function of the MET protein, and provides a platform for screening related drugs.

The present invention relates, in part, to chimeric proteins comprising a modified human IFN-γ having one or more mutations that confer reduced affinity and / or biological activity that is restorable by attachment to one or more targeting moieties. The one or more targeting moieties may have recognition domains which specifically bind to antigens or receptors of a tumor or an immune cell. The one or more recognition domains may be a single-domain antibody or a single-chain antibody (scFv). The application also provides use of the chimeric proteins as therapeutic agents.

An RSV virus-like particle which includes a chimeric protein that includes a core consisting of an influenza M1 protein, an RSV-derived preF protein, an RSV-derived G protein or part of G protein displayed on the surface of the core, can exhibit excellent effects in terms of inhibiting RSV virus infection and inhibiting the inflammatory response of the lungs.

The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.

The present invention describes chimeric proteins having albumin or truncated albumin covalently linked to one or more oxygen-binding proteins or protein fragments or variants, their preparation and use

The present application relates to compositions and methods for: (a) preventing or treating viral infections; and / or (b) preventing the transmission and / or spread of infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a virus, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating viral infections, preventing the transmission of a viral infection from an infected individual to a non-infected individual, and for preventing the spread of a viral infection within a population of individuals.

The present disclosure relates to chimeric Cry8 / Cry10 proteins, as well as variants and fragments thereof, methods and compositions for controlling insect pests, particularly coleopteran pests, more particularly sugarcane weevil pests of crop plant sugarcane. More specifically, the present disclosure relates to a novel chimeric protein named SCW109 for protecting sugar cane from infestation of sugar cane weevil. The present disclosure also relates to the production of pesticidal compositions using the proteins. In addition, the disclosure also relates to methods of using the proteins to control insect pests, more particularly coleopteran pests (e.g., sugar cane weevils).

The purpose of the present invention is to provide an agent for regenerating a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function regenerating ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-translocating receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-conjugated receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and / or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-translocating receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and / or a cytoplasm-side third loop in the G-protein-conjugated receptor rhodopsin.

The present invention provides fusion proteins comprising a fibroblast growth factor 1 (FGF1) peptide and a fibroblast growth factor 21 (FGF21) peptide. Pharmaceutical compositions and wound dressings comprising the fusion proteins, polynucleotides encoding the fusion proteins, and methods of using the fusion proteins to treat a condition in a subject are also provided.

Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

The present invention relates to optimized protein fusion linkers for the production of multifunctional chimeric proteins and methods of use thereof. Furthermore, the present invention relates to chimeric proteins for guided endonuclease systems.

The present invention relates, in part, to chimeric proteins comprising mutant interferon-γ and their use as therapeutic agents.